A 24-Month Study to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Participants With Early Alzheimer's Disease (MissionAD1)

January 14, 2021 updated by: Eisai Co., Ltd.

A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease

The name of this trial is MissionAD1. This phase 3 study consists of a Core and Open Label Extension (OLE) Phase in participants with Early Alzheimer's Disease (EAD), and will be conducted to evaluate the efficacy and safety of E2609. The Core is a 24-month treatment, multicenter, double blind, placebo controlled parallel group study. The OLE is a 24-month treatment, one group study. The data for the studies E2609-G000-301 (NCT02956486, MissionAD1) and E2609-G000-302 (NCT03036280, MissionAD2) will be pooled.

Study Overview

Status

Terminated

Conditions

Alzheimer's Disease

Intervention / Treatment

Study Type

Interventional

Enrollment (Actual)

2212

Phase

Phase 3

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

Argentina
- - Buenos Aires, Argentina, 1199
    - Facility #4
  - Caba, Argentina, C1428AQK
    - Facility #5
  - Cordoba, Argentina, X5004A0A
    - Facility #2
  - Cordoba, Argentina, X5009BIN
    - Facility #3
  - Santa Fe, Argentina, 3000
    - Facility #1
- Buenos Aires
  - Caba, Buenos Aires, Argentina, -1405
    - Facility #2
  - Caba, Buenos Aires, Argentina, C1012AAR
    - Facility #1
  - Caba, Buenos Aires, Argentina, C1126AAB
    - Facility #4
  - Caba, Buenos Aires, Argentina, C1427
    - Facility #3
  - Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina, 1111
    - Facility #1
  - Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina, 1430
    - Facility #3
  - Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina, C1230AAZ
    - Facility #2
- Capital
  - Cordoba, Capital, Argentina, X5003DCE
    - Facility #1
- Santa Fe
  - Rosario, Santa Fe, Argentina, 2000
    - Facility #1
Australia
- - Melbourne, Australia, 3146
    - Facility #3
- New South Wales
  - Darlinghurst, New South Wales, Australia, 2010
    - Facility #1
  - Macquarie Park, New South Wales, Australia, 2113
    - Facility #1
  - Tumbi Umbi, New South Wales, Australia, 2261
    - Facility #1
- Queensland
  - Brisbane, Queensland, Australia, 4032
    - Facility #1
- Victoria
  - Caulfield, Victoria, Australia, 3162
    - Facility #1
  - Geelong, Victoria, Australia, 3220
    - Facility #1
  - Heidelberg, Victoria, Australia, 3084
    - Facility #1
  - Malvern, Victoria, Australia, 3144
    - Facility #1
  - Melbourne, Victoria, Australia
    - Facility #2
  - Parkville, Victoria, Australia, 3050
    - Facility #1
- Western Australia
  - Nedlands, Western Australia, Australia, 6009
    - Facility #1
Austria
- - Vienna, Austria, 1130
    - Facility #1
Bulgaria
- - Pleven, Bulgaria, 5800
    - Facility #1
  - Plovdiv, Bulgaria, 4002
    - Facility #1
  - Ruse, Bulgaria, 7002
    - Facility #1
  - Sofia, Bulgaria, 1142
    - Facility #4
  - Sofia, Bulgaria, 1309
    - Facility #3
  - Sofia, Bulgaria, 1431
    - Facility #1
  - Sofia, Bulgaria, 1431
    - Facility #2
Canada
- British Columbia
  - Kamloops, British Columbia, Canada, V2C 5T1
    - Facility #1
  - Kelowna, British Columbia, Canada, V1Y 1Z9
    - Facility #1
  - West Vancouver, British Columbia, Canada, V7T 1C5
    - Facility #1
- Nova Scotia
  - Halifax, Nova Scotia, Canada, B3S 1M7
    - Facility #1
  - Kentville, Nova Scotia, Canada, B4N 4K9
    - Facility #1
- Ontario
  - Ottawa, Ontario, Canada, K1N 5C8
    - Facility #1
  - Peterborough, Ontario, Canada, K9H 2P4
    - Facility #1
- Quebec
  - Montreal, Quebec, Canada, H1M 1B1
    - Facility #1
  - Sherbrooke, Quebec, Canada, J1L 0H8
    - Facility #1
Czechia
- - Hradec Kralove, Czechia, 500 09
    - Facility #1
  - Kladno, Czechia, 272 01
    - Facility #1
  - Olomouc, Czechia, 779 00
    - Facility #1
  - Praha 10, Czechia, 109 00
    - Facility #1
France
- - Bordeaux, France, 33076
    - Facility #1
  - Bron Cedex, France, 69677
    - Facility #1
  - Marseille Cedex 05, France, 13385
    - Facility #1
  - Nantes, France, 44800
    - Facility #1
  - Paris, France, 75013
    - Facility #1
  - Rouen, France, 76000
    - Facility #1
  - Toulouse, France, 31059
    - Facility #1
- Herault
  - Montpellier, Herault, France, 34295
    - Facility #1
Germany
- - Berlin, Germany, 10245
    - Facility #1
  - Berlin, Germany, 10629
    - Facility #2
  - Gera, Germany, 7551
    - Facility #1
  - Homburg/Saar, Germany, 66241
    - Facility #1
  - Schwerin, Germany, 19053
    - Facility #1
- Bayern
  - Neuburg, Bayern, Germany, 86633
    - Facility #1
- Brandenburg
  - Hoppegarten, Brandenburg, Germany, 15366
    - Facility #1
  - Oranienburg, Brandenburg, Germany, 16515
    - Facility #1
- Hessen
  - Frankfurt, Hessen, Germany, 60528
    - Facility #1
- Saxony
  - Leipzig, Saxony, Germany, 4107
    - Facility #1
Greece
- - Athens, Greece, 11528
    - Facility #5
  - Athens, Greece, 15123
    - Facility #4
Japan
- - Kumamoto, Japan, 860-8556
    - EISAI Trial Site 1
  - Kyoto, Japan, 606-0851
    - EISAI Trial Site 3
  - Osaka, Japan, 553-0003
    - EISAI Trial Site 1
- Aichi
  - Anjo-shi, Aichi, Japan, 446-8510
    - EISAI Trial Site 1
  - Nagoya-shi, Aichi, Japan, 467-8602
    - EISAI Trial Site 1
  - Obu-shi, Aichi, Japan, 474-8511
    - EISAI Trial Site 1
- Fukui
  - Yoshida-gun, Fukui, Japan, 910-1193
    - EISAI Trial Site 1
- Fukuoka
  - Kitakyushu-shi, Fukuoka, Japan, 808-0024
    - Eisai Trail Site 1
  - Omuta-shi, Fukuoka, Japan, 837-0911
    - EISAI Trial Site 1
- Gunma
  - Fujioka-shi, Gunma, Japan, 375-0017
    - EISAI Trial Site 1
- Hiroshima
  - Otake-shi, Hiroshima, Japan, 739-0651
    - EISAI Trial Site 1
- Hyogo
  - Himeji, Hyogo, Japan, 671-1227
    - EISAI Trial Site 1
  - Himeji-shi, Hyogo, Japan, 670-0981
    - EISAI Trial Site 2
  - Kobe, Hyogo, Japan, 650-0017
    - EISAI Trial Site 1
- Kagawa
  - Miki, Kagawa, Japan, 761-0793
    - Facility #1
  - Takamatsu City, Kagawa, Japan, 760-8557
    - EISAI Trial Site 3
- Kanagawa
  - Fujisawa-shi, Kanagawa, Japan, 251-0038
    - EISAI Trial Site 1
- Kyoto
  - Kyoto City, Kyoto, Japan, 616-8255
    - EISAI Trial Site 4
  - Kyoto-shi, Kyoto, Japan, 602-8566
    - EISAI Trial Site 1
  - Kyoto-shi, Kyoto, Japan, 602-8566
    - EISAI Trial Site 2
  - Kyoto-shi, Kyoto, Japan, 607-8113
    - EISAI Trial Site 5
  - Shimogyo-ku, Kyoto, Japan, 600-8558
    - EISAI Trial Site 1
- Miyazaki
  - Higashimorokatagun, Miyazaki, Japan, 880-1111
    - EISAI Trial Site 1
- Okayama
  - Kurashiki-shi, Okayama, Japan, 710-0813
    - EISAI Trial Site 1
  - Kurashiki-shi, Okayama, Japan, 710-8692
    - EISAI Trial Site 2
  - Okayama-shi, Okayama, Japan, 700-8557
    - EISAI Trial Site 1
- Okayama-ken
  - Okayama-shi, Okayama-ken, Japan, 701-1192
    - EISAI Trial Site 2
- Osaka
  - Hirakata, Osaka, Japan, 573-1121
    - EISAI Trial Site 1
  - Naniwa-Ku, Osaka, Japan, 556-0017
    - EISAI Trial Site 1
  - Osaka-shi, Osaka, Japan, 534-0021
    - EISAI Trial Site 1
  - Osaka-shi, Osaka, Japan, 543-8555
    - EISAI Trial Site 3
  - Osaka-shi, Osaka, Japan, 545-8586
    - EISAI Trial Site 2
  - Sakai-shi, Osaka, Japan, 593-8301
    - EISAI Trial Site 2
  - Suita-shi, Osaka, Japan, 565-0871
    - EISAI Trial Site 1
  - Suita-shi, Osaka, Japan, 565-0874
    - EISAI Trial Site 2
  - Suminoe-ku, Osaka, Japan, 559-0004
    - EISAI Trial Site 1
- Saga
  - Kanzaki-gun, Saga, Japan, 842-0192
    - EISAI Trial Site 1
- Shiga
  - Otsu, Shiga, Japan, 520-0832
    - EISAI Trial Site 2
  - Otsu-shi, Shiga, Japan, 520-2192
    - EISAI Trial Site 1
- Tokushima
  - Tokushima-shi, Tokushima, Japan, 770-8503
    - EISAI Trial Site 1
- Tokyo
  - Bunkyo-ku, Tokyo, Japan, 113-0034
    - EISAI Trial Site 1
  - Bunkyo-ku, Tokyo, Japan, 113-8603
    - EISAI Trial Site 2
  - Kodaira-shi, Tokyo, Japan, 187-8551
    - EISAI Trial Site 1
  - Minato-ku, Tokyo, Japan, 108-0073
    - EISAI Trial Site 1
  - Setagaya-ku, Tokyo, Japan, 158-8531
    - EISAI Trial Site 1
  - Shinjuku-ku, Tokyo, Japan, 169-0073
    - EISAI Trial Site 1
  - Sumida-ku, Tokyo, Japan, 130-0004
    - EISAI Trial Site 1
- Yamaguchi
  - Hofu-shi, Yamaguchi, Japan, 747-0802
    - EISAI Trial Site 1
Korea, Republic of
- - Busan, Korea, Republic of, 49201
    - Facility #1
  - Incheon, Korea, Republic of, 22332
    - Facility #1
  - Seoul, Korea, Republic of, 3722
    - Facility #5
  - Seoul, Korea, Republic of, 4763
    - Facility #3
  - Seoul, Korea, Republic of, 5030
    - Facility #1
  - Seoul, Korea, Republic of, 6351
    - Facility #4
  - Seoul, Korea, Republic of, 6973
    - Facility #6
  - Seoul, Korea, Republic of, 7985
    - Facility #2
- Gyeonggi
  - Seongnam, Gyeonggi, Korea, Republic of, 13620
    - Facility #1
- Gyeonggi-do
  - Bucheon-si, Gyeonggi-do, Korea, Republic of, 14647
    - Facility #1
Poland
- - Katowice, Poland
    - Facility #1
  - Kielce, Poland, 25-411
    - Facility #1
  - Krakow, Poland, 30-149
    - Facility #1
  - Poznari, Poland, 61-853
    - Facility #1
  - Poznań, Poland
    - Facility #1
  - Siemianowice Śląskie, Poland, 41-100
    - Facility #1
  - Warszawa, Poland, 01-684
    - Facility #1
Portugal
- - Guimarães, Portugal, 4835-044
    - Facility #1
Russian Federation
- - Moscow, Russian Federation, 119991
    - Facility #1
Slovakia
- - Bratislava, Slovakia, 85107
    - Facility #1
Spain
- - Barcelona, Spain, 8028
    - Facility #1
  - Madrid, Spain, 28049
    - Facility #2
  - Madrid, Spain, 28223
    - Facility #1
  - Valencia, Spain, 46010
    - Facility #1
  - Valencia, Spain, 46026
    - Facility #2
- Alicante
  - Elche, Alicante, Spain, 3203
    - Facility #1
- Barcelona
  - Sant Cugat Del Valles, Barcelona, Spain, 8195
    - Facility #1
- Bizkaia
  - Getxo, Bizkaia, Spain, 48993
    - Facility #1
- Gipuzkoa
  - Donostia/San Sebastian, Gipuzkoa, Spain, 20009
    - Facility #1
- Illes Balears
  - Palma de Mallorca, Illes Balears, Spain, 7120
    - Facility #1
- Murcia
  - El Palmar, Murcia, Spain, 30120
    - Facility #1
United Kingdom
- - Glasgow, United Kingdom, G51 4TF
    - Facility #2
  - Guildford, United Kingdom, GU2 7YD
    - Facility #1
  - London, United Kingdom, W1G 9RU
    - Facility #1
  - London, United Kingdom, W6 8RF
    - Facility #4
  - London, United Kingdom, WC1X 8QD
    - Facility #3
- Cambridgeshire
  - Cambridge, Cambridgeshire, United Kingdom, CB21 5EF
    - Facility #1
- Cheshire
  - Chester, Cheshire, United Kingdom, CH2 1BQ
    - Facility #1
  - Winwick, Warrington, Cheshire, United Kingdom, WA2 8WA
    - Facility #1
- Devon
  - Plymouth, Devon, United Kingdom, PL6 8BT
    - Facility #1
- Dorset
  - Bournemouth, Dorset, United Kingdom, BH1 4JQ
    - Facility #1
- East Sussex
  - Crowborough, East Sussex, United Kingdom, TN6 1HB
    - Facility #1
- Greater Manchester
  - Manchester, Greater Manchester, United Kingdom, M13 9WL
    - Facility #1
- Hampshire
  - Southampton, Hampshire, United Kingdom, SO30 3JB
    - Facility #1
- Lanarkshire
  - Glasgow, Lanarkshire, United Kingdom, G20 0XA
    - Facility #1
- Lancashire
  - Blackpool, Lancashire, United Kingdom, FY2 0JH
    - Facility #1
  - Preston, Lancashire, United Kingdom, PR2 8DW
    - Facility #1
- Middlesex
  - London, Middlesex, United Kingdom, TW7 6FY
    - Facility #2
- North East Somerset
  - Bath, North East Somerset, United Kingdom, BA1 3NG
    - Facility #1
- Oxfordshire
  - Oxford, Oxfordshire, United Kingdom, OX3 7JX
    - Facility #1
- Scotland
  - Aberdeen, Scotland, United Kingdom, AB25 2ZH
    - Facility #1
- South Yorkshire
  - Sheffield, South Yorkshire, United Kingdom, S5 7JT
    - Facility #1
- Surrey
  - Leatherhead, Surrey, United Kingdom, KT22 7AD
    - Facility #1
- West Midlands
  - Birmingham, West Midlands, United Kingdom, B168QQ
    - Facility #1
- Wilts
  - Swindon, Wilts, United Kingdom, SN3 6BW
    - Facility #1
United States
- Arizona
  - Chandler, Arizona, United States, 85226
    - Facility #1
- California
  - Colton, California, United States, 92324
    - Facility #1
  - Costa Mesa, California, United States, 92626
    - Facility #1
  - Fullerton, California, United States, 92835
    - Facility #1
  - Imperial, California, United States, 92251
    - Facility #1
  - Irvine, California, United States, 92618
    - Facility #1
  - Lemon Grove, California, United States, 91945
    - Facility #1
  - Oceanside, California, United States, 92054
    - Facility #1
  - Oceanside, California, United States, 92054
    - Facility #2
  - Oxnard, California, United States, 93030
    - Facility #1
  - Panorama City, California, United States, 91402
    - Facility #1
  - San Diego, California, United States, 92123
    - Facility #1
- Colorado
  - Denver, Colorado, United States, 80218
    - Facility #1
- Florida
  - Atlantis, Florida, United States, 33462
    - Facility #1
  - Aventura, Florida, United States, 33187
    - Facility #1
  - Aventura, Florida, United States, 33187
    - Facility #2
  - Boynton Beach, Florida, United States, 33437
    - Facility #1
  - Coral Gables, Florida, United States, 33134
    - Facility #1
  - Coral Gables, Florida, United States, 33134
    - Facility #2
  - Delray Beach, Florida, United States, 33445
    - Facility #1
  - Doral, Florida, United States, 33122
    - Facility #1
  - Hialeah, Florida, United States, 33016
    - Facility #1
  - Miami, Florida, United States, 33137
    - Facility #1
  - Miami, Florida, United States, 33122
    - Facility #2
  - Miami, Florida, United States, 33125
    - Facility #11
  - Miami, Florida, United States, 33125
    - Facility #9
  - Miami, Florida, United States, 33126
    - Facility #10
  - Miami, Florida, United States, 33133
    - Facility #4
  - Miami, Florida, United States, 33144
    - Facility #6
  - Miami, Florida, United States, 33155
    - Facility #3
  - Miami, Florida, United States, 33174
    - Facility #7
  - Miami, Florida, United States, 33176
    - Facility #8
  - Orlando, Florida, United States, 32806
    - Facility #1
  - Orlando, Florida, United States, 32801
    - Facility #2
  - Orlando, Florida, United States, 32807
    - Facility #3
  - Palm Beach Gardens, Florida, United States, 33410
    - Facility #1
  - Pompano Beach, Florida, United States, 33064
    - Facility #1
  - Port Charlotte, Florida, United States, 33952
    - Facility #1
  - Port Orange, Florida, United States, 32127
    - Facility #1
  - Spring Hill, Florida, United States, 34609
    - Facility #1
  - Tampa, Florida, United States, 33613
    - Facility #1
  - Tampa, Florida, United States, 33614
    - Facility #2
  - The Villages, Florida, United States, 32162
    - Facility #1
- Georgia
  - Atlanta, Georgia, United States, 30328
    - Facility #1
  - Columbus, Georgia, United States, 31909
    - Facility #1
  - Decatur, Georgia, United States, 30033
    - Facility #1
  - Suwanee, Georgia, United States, 30024
    - Facility #1
- Idaho
  - Meridian, Idaho, United States, 83642
    - Facility #1
- Illinois
  - Northbrook, Illinois, United States, 60062
    - Facility #1
- Kansas
  - Wichita, Kansas, United States, 67214
    - Facility #2
- Massachusetts
  - Boston, Massachusetts, United States, 2115
    - Facility #1
- Michigan
  - Farmington Hills, Michigan, United States, 48334
    - Facility #1
- Missouri
  - Chesterfield, Missouri, United States, 63005
    - Facility #1
  - O'Fallon, Missouri, United States, 63368
    - Facility #1
  - Saint Louis, Missouri, United States, 63104
    - Facility #2
  - Saint Peters, Missouri, United States, 63303
    - Facility #1
- New Jersey
  - Mount Arlington, New Jersey, United States, 7856
    - Facility #1
  - Springfield, New Jersey, United States, 7081
    - Facility #2
  - West Long Branch, New Jersey, United States, 7764
    - Facility #1
- New York
  - Amherst, New York, United States, 14226
    - Facility #1
  - Brooklyn, New York, United States, 11229
    - Facility #1
  - New York, New York, United States, 10032
    - Facility #1
- Ohio
  - Canton, Ohio, United States, 44718
    - Facility #1
  - Centerville, Ohio, United States, 45459
    - Facility #1
  - Cleveland, Ohio, United States, 44195
    - Facility #1
  - Dayton, Ohio, United States, 45459
    - Facility #1
  - Lakewood, Ohio, United States, 44107
    - Facility #1
  - Westerville, Ohio, United States, 43081
    - Facility #1
- Oklahoma
  - Oklahoma City, Oklahoma, United States, 73116
    - Facility #1
- Oregon
  - Portland, Oregon, United States, 97210
    - Facility #1
- Pennsylvania
  - Jenkintown, Pennsylvania, United States, 19046
    - Facility #1
  - Media, Pennsylvania, United States, 19063
    - Facility #1
  - Philadelphia, Pennsylvania, United States, 19104
    - Facility #1
- Rhode Island
  - East Providence, Rhode Island, United States, 02914
    - Facility #1
  - Providence, Rhode Island, United States, 2906
    - Facility #1
- South Carolina
  - Port Royal, South Carolina, United States, 29935
    - Facility #1
- Tennessee
  - Cordova, Tennessee, United States, 38018
    - Facility #1
  - Nashville, Tennessee, United States, 37203
    - Facility #2
  - Nashville, Tennessee, United States, 37212
    - Facility #1
- Texas
  - Austin, Texas, United States, 78757
    - Facility #1
  - Dallas, Texas, United States, 75231
    - Facility #1
  - Houston, Texas, United States, 77084
    - Facility #1
  - San Antonio, Texas, United States, 78229-3900
    - Facility #1
  - San Antonio, Texas, United States, 78240
    - Facility #3
- Utah
  - Salt Lake City, Utah, United States, 84108
    - Facility #1
- Vermont
  - Bennington, Vermont, United States, 5201
    - Facility #1
- Virginia
  - Hampton, Virginia, United States, 23666
    - Facility #1
- Wisconsin
  - Madison, Wisconsin, United States, 53705
    - Facility #1

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

50 years to 85 years (Adult, Older Adult)

Accepts Healthy Volunteers

Genders Eligible for Study

All

Description

Inclusion Criteria:

Core Study

Mild cognitive impairment due to Alzheimer's disease (AD) or mild AD dementia including
1. Mini Mental State Examination score equal to or greater than 24
2. Clinical Dementia Rating (CDR) global score of 0.5
3. CDR Memory Box score of 0.5 or greater
Impaired episodic memory confirmed by a list learning task
Positive biomarker for brain amyloid pathology as indicated by either amyloid positron emission tomography or cerebrospinal fluid AD assessment or both

Extension Phase

• Participants who complete the Core Study

Exclusion Criteria:

Core Study

Females who are breastfeeding or pregnant at Screening or Baseline. Females of child-bearing potential must use a highly effective method of contraception throughout the entire study period and for 28 days after study drug discontinuation
Any condition that may be contributing to cognitive impairment above and beyond that caused by the participant's AD
Participants with a history of seizures within 5 years of Screening
History of transient ischemic attacks or stroke within 12 months of Screening
Psychiatric diagnosis or symptoms (example, hallucinations, major depression, delusions etc.)
Suicidal ideation or any suicidal behavior within 6 months before Screening or has been hospitalized or treated for suicidal behavior in the past 5 years
Have any contraindications to magnetic resonance imaging (MRI) scanning or
1. Have lesions that could indicate a dementia diagnosis other than AD on brain MRI
2. Exhibit other significant pathological findings on brain MRI.
Participants who have a history of moderate to severe hepatic impairment (example, Child-Pugh Class B or C)
Results of laboratory tests conducted during Screening that are outside the following limits:
1. Absolute lymphocyte count below the lower limit of normal (LLN)
2. Thyroid stimulating hormone above normal range
3. Abnormally low Vitamin B12 levels
Participants at increased risk of infection
Have received any live vaccine/live attenuated vaccine in the 3 months before randomization
Any chronic inflammatory disease that is not adequately controlled or that requires systemic immunosuppressive or immunomodulatory therapy
Any other clinically significant abnormalities
Severe visual or hearing impairment
A prolonged corrected QT (QTc) interval (QT interval with Fridericia's correction [QTcF] greater than 450 milliseconds [ms])
Malignant neoplasms within 5 years of Screening
Known or suspected history of drug or alcohol abuse
Taking prohibited medications, which must be reviewed with the Investigator
Have participated in a recent clinical study

Note: Other protocol-defined Inclusion/Exclusion Criteria may apply.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Interventional Model: Parallel Assignment
Masking: Quadruple

Number of Arms

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Core Study: Elenbecestat 50 mg Participants will receive one 50 milligram (mg) elenbecestat tablet, orally, once a day in the morning. The core study will be double blinded.	Drug: Elenbecestat Oral tablet. Other Names: E2609
Placebo Comparator: Core Study: Placebo Participants will receive one matching placebo tablet, orally, once a day in the morning. The core study will be double blinded.	Drug: Placebo Oral tablet.
Experimental: Open-label Extension Phase: Elenbecestat 50 mg Participants completing the core study will receive one 50 mg elenbecestat tablet, orally, once a day in the morning.	Drug: Elenbecestat Oral tablet. Other Names: E2609

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Core Phase: Change From Baseline up to Month 24 in the Clinical Dementia Rating-sum of Boxes (CDR-SB) Score Time Frame: Baseline (Day 1: before first dose in the core phase) up to Month 24 of the core phase	The clinical dementia rating (CDR) scale is a clinical global rating scale that requires interviewing both the participant and an informant who knows and has contact with the participant. The CDR scale is a clinician directed assessment of both cognition and function, and is intended to capture the state and therefore the disease stage of the participant. The CDR scale assesses 6 domains of participant function (memory, orientation, judgement and problem solving, community affairs, home and hobbies and personal care) on a 5-point scale in which no impairment=0, questionable impairment=0.5, mild impairment=1, moderate impairment=2 and severe impairment=3. The CDR-SB is a sum of the individual domain scores and ranges from 0 to 18. Higher score indicates more impairment.	Baseline (Day 1: before first dose in the core phase) up to Month 24 of the core phase
Extension Phase: Number of Participants Reporting One or More Treatment-emergent Adverse Events (TEAEs) Time Frame: From first dose of study drug up to approximately 6 months (including 1 month follow up) for the extension phase	A TEAE is defined as an adverse event that emerged during treatment or within 28 days following the last dose of study drug, having been absent at pretreatment (Baseline) or reemerged during treatment, having been present at pretreatment (Baseline) but stopped before treatment, or worsened in severity during treatment relative to the pretreatment state, when the adverse event was continuous. Number of participants with TEAEs (serious and non-serious adverse events) were reported based on their safety assessments of laboratory tests, suicidal ideation and suicidal behavior, drug abuse potential, physical examination, neurological examination, regular measurement of vital signs, magnetic resonance imaging and electrocardiogram parameter values.	From first dose of study drug up to approximately 6 months (including 1 month follow up) for the extension phase

Secondary Outcome Measures

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Eisai Co., Ltd.

Collaborators

Biogen

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Bullich S, Mueller A, De Santi S, Koglin N, Krause S, Kaplow J, Kanekiyo M, Roe-Vellve N, Perrotin A, Jovalekic A, Scott D, Gee M, Stephens A, Irizarry M. Evaluation of tau deposition using 18F-PI-2620 PET in MCI and early AD subjects-a MissionAD tau sub-study. Alzheimers Res Ther. 2022 Jul 27;14(1):105. doi: 10.1186/s13195-022-01048-x.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

October 20, 2016

Primary Completion (Actual)

January 15, 2020

Study Completion (Actual)

January 15, 2020

Study Registration Dates

First Submitted

November 3, 2016

First Submitted That Met QC Criteria

November 3, 2016

First Posted (Estimate)

November 6, 2016

Study Record Updates

Last Update Posted (Actual)

February 3, 2021

Last Update Submitted That Met QC Criteria

January 14, 2021

Last Verified

January 1, 2021

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

E2609-G000-301
2016-003928-23 (EudraCT Number)
2016-004128-42 (EudraCT Number)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

Undecided

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

Yes

Studies a U.S. FDA-regulated device product

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Alzheimer's Disease

University of Saskatchewan
Center of Molecular Immunology, Cuba

Not yet recruiting

Evaluation of the Safety and Efficacy of NeuroEPO in Subjects With Mild to Moderate Alzheimer's Disease

Mild Alzheimer's Disease | Moderate Alzheimer's Disease

Canada
University of Southern California
Alzheimer's Therapeutic Research Institute; American Heart Association; Schaeffer...

Completed

Financial Incentives and Recruitment to the APT Webstudy (FIND-AD)

Dementia | Alzheimer Disease | Prodromal Alzheimer's Disease | Preclinical Alzheimer's Disease

United States
University of Southern California
National Institute on Aging (NIA); Alzheimer's Therapeutic Research Institute; Brigham and Women's Hospital and other collaborators

Completed

TRC-PAD Program: In-Clinic Trial-Ready Cohort (TRC-PAD)

Dementia | Alzheimer Disease | Prodromal Alzheimer's Disease | Preclinical Alzheimer's Disease

United States
Novoic Limited

Recruiting

Amyloid Prediction in Early Stage Alzheimer's Disease From Acoustic and Linguistic Patterns of Speech - PAST Extension (AMYPRED-PAST)

Alzheimer Disease | Mild Cognitive Impairment | Prodromal Alzheimer's Disease | Alzheimer's Disease (Incl Subtypes) | Preclinical Alzheimer's Disease

United Kingdom
Novoic Limited

Terminated

Amyloid Prediction in Early Stage Alzheimer's Disease Through Speech Phenotyping - FUTURE Extension (FUTURE-US)

Alzheimer Disease | Mild Cognitive Impairment | Prodromal Alzheimer's Disease | Alzheimer's Disease (Incl Subtypes) | Preclinical Alzheimer's Disease

United States
Novoic Limited

Completed

Amyloid Prediction in Early Stage Alzheimer's Disease Through Speech Phenotyping (AMYPRED-US)

Alzheimer Disease | Mild Cognitive Impairment | Prodromal Alzheimer's Disease | Alzheimer's Disease (Incl Subtypes) | Preclinical Alzheimer's Disease

United States
Novoic Limited

Completed

Amyloid Prediction in Early Stage Alzheimer's Disease From Acoustic and Linguistic Patterns of Speech (AMYPRED)

Alzheimer Disease | Mild Cognitive Impairment | Prodromal Alzheimer's Disease | Alzheimer's Disease (Incl Subtypes) | Preclinical Alzheimer's Disease

United Kingdom
University of Southern California
Alzheimer's Therapeutic Research Institute; Alzheimer's Association; Alzheimer...

Active, not recruiting

Alzheimer's Plasma Extension (APEX)

Preclinical Alzheimer's Disease | Early Preclinical Alzheimer's Disease

United States
Novoic Limited

Terminated

Amyloid Prediction in Early Stage Alzheimer's Disease From Acoustic and Linguistic Patterns of Speech - FUTURE Extension (AMYPRED-FUTURE)

Alzheimer Disease | Mild Cognitive Impairment | Prodromal Alzheimer's Disease | Alzheimer's Disease (Incl Subtypes) | Preclinical Alzheimer's Disease

United Kingdom
Novoic Limited

Recruiting

Amyloid Prediction in Early Stage Alzheimer's Disease Through Speech Phenotyping - PAST Extension (PAST-US)

Alzheimer Disease | Mild Cognitive Impairment | Prodromal Alzheimer's Disease | Alzheimer's Disease (Incl Subtypes) | Preclinical Alzheimer's Disease | Normal Cognition

United States

Clinical Trials on Placebo

Galderma R&D

Completed

Effect of CD07805/47 Gel in Rosacea Flushing

Rosacea

Germany
SamA Pharmaceutical Co., Ltd

Unknown

Clinical Trials to Assess the Efficacy and Safety of HLIM

Acute Bronchitis | Acute Upper Respiratory Tract Infection

Korea, Republic of
National Institute on Drug Abuse (NIDA)

Completed

Effects of Cannabis Administration Routes on Human Performance and Pharmacokinetics

Cannabis Use

United States
Akeso

Not yet recruiting

A Clinical Study of AK120 in Adolescents With Moderate-to-severe Atopic Dermatitis

Atopic Dermatitis

China
AstraZeneca
Parexel; Spandauer Damm 130; 14050; Berlin, Germany

Completed

Assessment of the Safety, Tolerability and Pharmacodynamics After Administration of One Dose of AZD8601 to Male Patients With Type II Diabetes Mellitus (T2DM)

Male Subjects With Type II Diabetes (T2DM)

Germany
Heptares Therapeutics Limited

Completed

Pharmacokinetics of Oral Capsule in Healthy Japanese vs. Caucasian Subjects (HTL0018318)

Pharmacokinetics | Safety Issues

United Kingdom
GlaxoSmithKline

Completed

A Clinical Study Assessing Critical Errors, Training/Teaching Time, and Preference Attributes of the ELLIPTA® Dry Powder Inhaler, in Comparison to Combinations of Dry Powder Inhalers Used to Provide Triple Therapy, in Patients With Chronic Obstructive Pulmonary Disease

Pulmonary Disease, Chronic Obstructive

United Kingdom, Netherlands
Shijiazhuang Yiling Pharmaceutical Co. Ltd
Xuanwu Hospital, Beijing

Completed

Study on the Safety, Tolerance and Pharmacokinetics of Phenlarmide Tablets

Parkinson Disease

China
GlaxoSmithKline

Completed

A Study to Investigate the Safety, Tolerability and Pharmacokinetics of Oral and Intravenous GSK1322322 in Healthy Subjects

Infections, Bacterial

United States
West Penn Allegheny Health System

Completed

Sunovion Growth Study Pediatric Subjects With Mild Asthma & Allergic Rhinitis

Asthma | Allergic Rhinitis

United States

A 24-Month Study to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Participants With Early Alzheimer's Disease (MissionAD1)

A Placebo-Controlled, Double-Blind, Parallel-Group, 24 Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease

Study Overview

Status

Conditions

Intervention / Treatment

Study Type

Enrollment (Actual)

Phase

Contacts and Locations

Study Locations

Participation Criteria

Eligibility Criteria

Ages Eligible for Study

Accepts Healthy Volunteers

Genders Eligible for Study

Description

Study Plan

How is the study designed?

Design Details

Number of Arms

Arms and Interventions

Participant Group / Arm

Intervention / Treatment

What is the study measuring?

Primary Outcome Measures

Outcome Measure

Measure Description

Time Frame

Secondary Outcome Measures

Outcome Measure

Measure Description

Time Frame

Collaborators and Investigators

Sponsor

Collaborators

Publications and helpful links

General Publications

Study record dates

Study Major Dates

Study Start (Actual)

Primary Completion (Actual)

Study Completion (Actual)

Study Registration Dates

First Submitted

First Submitted That Met QC Criteria

First Posted (Estimate)

Study Record Updates

Last Update Posted (Actual)

Last Update Submitted That Met QC Criteria

Last Verified

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

Studies a U.S. FDA-regulated device product

Clinical Trials on Alzheimer's Disease

Clinical Trials on Placebo

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Armenia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations